Researchers at the University of North Carolina have developed a new immunotherapy approach that may offer a safer and more effective treatment for acute myeloid leukemia (AML), a deadly blood cancer. The team, led by immunologist Gianpietro Dotti and hematologist Paul Armistead, engineered immune cells capable of destroying cancerous cells while leaving healthy blood tissue unharmed, overcoming a key limitation of existing therapies that often struggle to distinguish between malignant and normal cells.
The findings, published in the journal Blood, represent a significant step forward in cancer immunotherapy. Standard treatments for AML, such as chemotherapy and stem cell transplants, can be highly toxic and often fail to prevent relapse. The new approach, which involves genetically modifying immune cells to recognize and attack AML cells without harming healthy blood cells, could lead to more targeted and less harmful treatments.
“The ability to separate cancerous cells from normal cells has been a major challenge in treating AML,” the researchers noted. Their engineered immune cells are designed to specifically target antigens present on leukemia cells while sparing healthy hematopoietic stem cells. This precision could reduce side effects and improve patient outcomes.
The potential impact of this research extends beyond AML. The study could pave the way for similar approaches against other cancers, particularly those where healthy and cancerous cells are difficult to distinguish. Further research may lead to even more advanced, side-effect-free cancer therapies, according to the scientists.
Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also focused on developing innovative cancer treatments, highlighting a growing industry interest in next-generation immunotherapies. However, the UNC team’s work is specifically noted for its potential to directly improve AML treatment, a disease with a five-year survival rate of only about 30%.
The study’s publication in Blood, a leading hematology journal, underscores its significance to the medical community. If replicated in clinical trials, this approach could offer new hope to patients with AML, particularly those who are older or have relapsed after standard therapy.
This research was conducted at the University of North Carolina Lineberger Comprehensive Cancer Center, with support from the National Institutes of Health and other funding sources. The findings are expected to inform future clinical trials, bringing the therapy closer to patient use.
